Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide

Carfilzomib-lenalidomide-dexamethasone (KRd) therapy has yielded promising results in patients with newly diagnosed multiple myeloma (NDMM). Cereblon (CRBN) is the direct molecular target of lenalidomide and genetic polymorphisms in CRBN have been associated with lenalidomide efficacy. In this study...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Sci Rep
Egile Nagusiak: Huang, Phoebe A., Beedie, Shaunna L., Chau, Cindy H., Venzon, David J., Gere, Sheryl, Kazandjian, Dickran, Korde, Neha, Mailankody, Sham, Landgren, Ola, Figg, William D.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group UK 2019
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6795854/
https://ncbi.nlm.nih.gov/pubmed/31619706
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-51446-9
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak